NKTR: Nektar Therapeutics
Performance
NKTR -32.42%
Watchlist
Select an item
Summary
NKTR at a glance
NKTR returned -32.42% over the past year and -28.39% a year over five years. Its worst drop in that year was -64.34%, smaller than 9% of stocks on Redstone, and its Sharpe ratio of -0.13 beats 22% of stocks on Redstone. It pays no dividends.
Current Drawdown
-62.31%
Rolling Volatility
53.12%
Actions
Metrics
Risk Indicators
Alpha-21.06%
Beta1.06x
Sharpe-0.13
Sortino-0.22
Omega0.97
Calmar-0.50
Martin-0.32
Profile
About NKTR
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $1.3B
- Listed
- May 1994
- Employees
- 63
- Headquarters
- San Francisco, CA
- Website
- nektar.com
Comparisons